In HM3KO melanoma cells, nilotinib was found to upregulate MITF and its downstream genes by activation of the cAMP/PKA/CREB signaling pathway and decreasing the phosphorylation of AKT, which repressed the pigmentation process by inhibition of GSK3β 179. This evidence concerns the gene GSK3B and melanoma.